Insulin isophane
FDA approved · RxIntermediate-acting insulin
Also known as: NPH insulin, Caninsulin, Monotard, Insulin lente, Insulin semilente, Novolin U, Insulin lente MC, Insulin NPH
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 185 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Insulin isophane, commonly called NPH insulin, is human insulin combined with the protein protamine and zinc, which slows its absorption after injection under the skin. Like the body's own insulin, it acts on insulin receptors to help cells take up glucose and to reduce glucose production by the liver, with an intermediate duration of action.
What the evidence shows
NPH insulin is a long-established prescription insulin approved for improving blood sugar control in people with diabetes, supported by a large body of human research including 185 registered trials reaching Phase 4. The supplied database record did not confirm a specific FDA approval listing or brand name, but its prescription status and clinical use are well documented.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes
Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Premixed insulin analogues for the treatment of diabetes mellitus.
Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Use of insulin glargine during pregnancy: a case-control pilot study.
Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial.
Sources
- PubChem compound record (CID 24839622)
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.